MCID: FLL003
MIFTS: 33

Fallopian Tube Endometrioid Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Endometrioid Adenocarcinoma:

Name: Fallopian Tube Endometrioid Adenocarcinoma 11 14 71
Endometrioid Carcinoma of the Fallopian Tube 11
Fallopian Tube Endometrioid Neoplasm 11
Fallopian Tube Endometrioid Cancer 11
Fallopian Tube Endometrioid Tumor 71

Classifications:



External Ids:

Disease Ontology 11 DOID:5831
NCIt 49 C40111 C6279
UMLS 71 C1333592 C1517113

Summaries for Fallopian Tube Endometrioid Adenocarcinoma

Disease Ontology: 11 A fallopian tube adenocarcinoma that derives from endometrial epithelial cells of glandular origin.

MalaCards based summary: Fallopian Tube Endometrioid Adenocarcinoma, also known as endometrioid carcinoma of the fallopian tube, is related to wolffian duct adenoma and fallopian tube adenocarcinoma. An important gene associated with Fallopian Tube Endometrioid Adenocarcinoma is CALB2 (Calbindin 2). The drugs Topotecan and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, and related phenotypes are endocrine/exocrine gland and embryo

Related Diseases for Fallopian Tube Endometrioid Adenocarcinoma

Diseases related to Fallopian Tube Endometrioid Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 wolffian duct adenoma 30.9 PAX8 PAX2 MME
2 fallopian tube adenocarcinoma 30.6 PAX8 CALB2
3 endometrial cancer 30.4 PMS2 MUC16 MME ERBB2 CDKN2A CALB2
4 papillary serous adenocarcinoma 30.4 PAX8 ERBB2 CALB2
5 fallopian tube carcinoma 30.2 RAD51C PAX8 ERBB2 CALB2
6 female reproductive endometrioid cancer 29.6 PMS2 PAX8 ERBB2 ARID1A
7 serous cystadenocarcinoma 27.6 RAD51C PMS2 PAX8 PAX2 MUC16 HNF1B
8 adenocarcinoma 10.5
9 endometriosis 10.4
10 pacinian tumor 10.3 MME CALB2
11 malignant glandular tumor of peripheral nerve sheath 10.3 MYOG CALB2
12 uterine inversion 10.3 MYOG MME
13 adult type testicular granulosa cell tumor 10.3 MME CALB2
14 heart lymphoma 10.3 MYOG MME
15 sigmoid disease 10.3 MME CALB2
16 scrotum neoplasm 10.3 MYOG CALB2
17 lung sarcoma 10.3 MYOG CALB2
18 myoblastoma 10.3 MYOG CALB2
19 female urethral cancer 10.3 MME CDKN2A
20 cervical polyp 10.3 MYOG MME
21 monophasic synovial sarcoma 10.3 MYOG CALB2
22 early invasive cervical adenocarcinoma 10.3 INSM1 CDKN2A
23 epithelioid leiomyosarcoma 10.3 MYOG MME
24 large cell carcinoma with rhabdoid phenotype 10.3 MYOG CALB2
25 heart sarcoma 10.3 MYOG CALB2
26 sarcomatoid squamous cell skin carcinoma 10.3 MYOG MME
27 papillary squamous carcinoma 10.3 INSM1 CDKN2A
28 breast metaplastic carcinoma 10.3 MME ERBB2
29 skin sarcoma 10.3 MME CDKN2A
30 vulval paget's disease 10.3 ERBB2 CDKN2A
31 vagina sarcoma 10.3 MYOG MME
32 vulva basal cell carcinoma 10.3 ERBB2 CDKN2A
33 breast sarcoma 10.3 MYOG ERBB2
34 tuberculous peritonitis 10.3 MUC16 CALB2
35 ovarian sex-cord stromal tumor 10.3 MME CALB2
36 breast malignant phyllodes tumor 10.3 MME ERBB2
37 pancreatoblastoma 10.3 MME CDKN2A
38 cervical carcinosarcoma 10.2 MYOG MME CALB2
39 sarcomatoid mesothelioma 10.2 CDKN2A CALB2
40 chronic cervicitis 10.2 INSM1 CDKN2A
41 endometriosis of ovary 10.2
42 leiomyoma 10.2
43 rare tumor 10.2
44 heart cancer 10.2 MYOG CALB2
45 intraductal breast benign neoplasm 10.2 MME ERBB2
46 basaloid squamous cell carcinoma 10.2 INSM1 CDKN2A
47 endometrial stromal sarcoma 10.2 MYOG MME CALB2
48 perivascular epithelioid cell tumor 10.2 PAX8 MME
49 microinvasive cervical squamous cell carcinoma 10.2 PTPRN INSM1
50 rete testis neoplasm 10.2 PAX8 CALB2

Graphical network of the top 20 diseases related to Fallopian Tube Endometrioid Adenocarcinoma:



Diseases related to Fallopian Tube Endometrioid Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Endometrioid Adenocarcinoma

MGI Mouse Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 ARID1A CCNE1 CDKN2A ERBB2 HNF1B INSM1
2 embryo MP:0005380 9.81 ARID1A CCNE1 CDKN2A ERBB2 HNF1B MYOG
3 no phenotypic analysis MP:0003012 9.8 ARID1A CDKN2A EMSY INSM1 MYOG PAX8
4 cellular MP:0005384 9.7 ARID1A CCNE1 CDKN2A ERBB2 HNF1B INSM1
5 reproductive system MP:0005389 9.32 ARID1A CCNE1 CDKN2A ERBB2 MUC16 PAX2

Drugs & Therapeutics for Fallopian Tube Endometrioid Adenocarcinoma

Drugs for Fallopian Tube Endometrioid Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
2
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
7
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
10
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
11
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
12
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-16-7, 110-17-8 444266 444972
13
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
14 Carotenoids Phase 3
15 Trace Elements Phase 3
16 Micronutrients Phase 3
17 Immunoglobulins, Intravenous Phase 2, Phase 3
18 Anti-Bacterial Agents Phase 2, Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20 Immunoglobulins Phase 2, Phase 3
21 topoisomerase I inhibitors Phase 2, Phase 3
22 Immunoglobulin G Phase 2, Phase 3
23 Antimitotic Agents Phase 3
24 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
25 Tubulin Modulators Phase 3
26 Antibodies, Monoclonal Phase 2, Phase 3
27 Antibodies Phase 2, Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3
29 Liposomal doxorubicin Phase 2, Phase 3
30 Antineoplastic Agents, Immunological Phase 2, Phase 3
31 Immunologic Factors Phase 2, Phase 3
32 Protein Kinase Inhibitors Phase 2, Phase 3
33 Angiogenesis Inhibitors Phase 2, Phase 3
34 Endothelial Growth Factors Phase 2, Phase 3
35 Mitogens Phase 2, Phase 3
36 Taxane Phase 3 108169
37 Antiviral Agents Phase 3
38 Anti-Infective Agents Phase 3
39 Antimetabolites Phase 3
40 Immunosuppressive Agents Phase 3
41
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
42
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
43
Durvalumab Approved, Investigational Phase 2 1428935-60-7
44
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
45
Ipilimumab Approved Phase 2 477202-00-9
46
Tremelimumab Approved, Investigational Phase 2 745013-59-6
47
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
48 Alkylating Agents Phase 2
49 Antirheumatic Agents Phase 2
50 Antineoplastic Agents, Alkylating Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
5 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
8 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
10 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
11 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
12 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
13 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
14 Life on the Go 2: Evaluating the Effect of Physical Activity of Patients With Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device Completed NCT03685695 Phase 2
15 A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
16 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
17 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
18 A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy Recruiting NCT05295589 Phase 2 Copanlisib Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
19 A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
20 A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer Active, not recruiting NCT03587311 Phase 2 Paclitaxel
21 A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
22 A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Active, not recruiting NCT04034927 Phase 2 Olaparib
23 Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer Not yet recruiting NCT05231122 Phase 2
24 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
25 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
26 Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 Recruiting NCT05276973 Phase 1 Carboplatin;Ipatasertib;Paclitaxel
27 A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Recruiting NCT04092270 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
28 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
29 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Terminated NCT03924245 Phase 1 Entinostat;Olaparib
30 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Completed NCT01504126 Early Phase 1 Chemotherapy;Propranolol Hydrochloride
31 Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Recruiting NCT05415709 Early Phase 1 Carboplatin;Cisplatin;Hyperthermic Intraperitoneal Chemotherapy;Paclitaxel
32 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1
33 A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy Terminated NCT00899093
34 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Terminated NCT03641287

Search NIH Clinical Center for Fallopian Tube Endometrioid Adenocarcinoma

Genetic Tests for Fallopian Tube Endometrioid Adenocarcinoma

Anatomical Context for Fallopian Tube Endometrioid Adenocarcinoma

Organs/tissues related to Fallopian Tube Endometrioid Adenocarcinoma:

MalaCards : Endothelial

Publications for Fallopian Tube Endometrioid Adenocarcinoma

Articles related to Fallopian Tube Endometrioid Adenocarcinoma:

(show all 13)
# Title Authors PMID Year
1
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a case of report and review of the literature. 62
19457622 2010
2
Primary fallopian tube carcinoma associated with ovulation induction; a case report. 62
18217974 2008
3
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review. 62
15991543 2005
4
Endometrioid carcinoma of the fallopian tube resembling a female adnexal tumor of probable wolffian origin. 62
15322493 2004
5
[Endometrioid carcinoma of the Fallopian tube arising in tubo-ovarian endometriosis. A case report]. 62
12659783 2003
6
A case of endometrioid carcinoma of the fallopian tube mimicking an adnexal tumor of probable Wolffian origin. 62
10379682 1999
7
Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study. 62
10079381 1999
8
Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. 62
8946874 1996
9
Primary endometrioid carcinoma of the fallopian tube. 62
8677782 1996
10
Microcystic endometrioid carcinoma of the fallopian tube simulating an adnexal tumour of probable wolffian origin. 62
8314244 1993
11
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a report of six cases. 62
1582746 1992
12
Endometrioid carcinoma of the fallopian tube: pathology and clinical outcome. 62
1972104 1990
13
Endometrioid carcinoma of the fallopian tube. 62
683640 1978

Variations for Fallopian Tube Endometrioid Adenocarcinoma

Expression for Fallopian Tube Endometrioid Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Endometrioid Adenocarcinoma.

Pathways for Fallopian Tube Endometrioid Adenocarcinoma

GO Terms for Fallopian Tube Endometrioid Adenocarcinoma

Biological processes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 anatomical structure development GO:0048856 9.97 PAX8 PAX2 MYOG
2 mesonephros development GO:0001823 9.88 PAX8 PAX2
3 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.86 PAX8 PAX2
4 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.85 PAX8 PAX2
5 metanephric epithelium development GO:0072207 9.83 PAX8 PAX2
6 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.8 PAX2 PAX8
7 metanephric distal convoluted tubule development GO:0072221 9.78 PAX2 PAX8
8 metanephric nephron tubule formation GO:0072289 9.76 PAX2 PAX8
9 negative regulation of immature T cell proliferation in thymus GO:0033088 9.71 ERBB2 CDKN2A
10 pronephric field specification GO:0039003 9.71 PAX2 PAX8
11 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.67 PAX2 PAX8
12 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.62 PAX2 PAX8
13 nephric duct formation GO:0072179 9.61 PAX2 HNF1B
14 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.56 PAX2 PAX8
15 mesonephric tubule development GO:0072164 9.51 PAX8 HNF1B
16 positive regulation of metanephric DCT cell differentiation GO:2000594 9.46 PAX2 PAX8
17 pronephros development GO:0048793 9.43 PAX8 PAX2 HNF1B
18 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.1 PAX8 PAX2 HNF1B

Molecular functions related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.47 RAD51C PMS2 PAX8 PAX2 MYOG INSM1
2 cis-regulatory region sequence-specific DNA binding GO:0000987 9.26 PAX2 MYOG HNF1B

Sources for Fallopian Tube Endometrioid Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....